Skip to content
Osoresnontrine
Osoresnontrine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchizophreniaD012559EFO_0000692F20224
Alzheimer diseaseD000544EFO_0000249F03123
Psychotic disordersD011618F20.8111
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients1616
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOSORESNONTRINE
INNosoresnontrine
Description
Osoresnontrine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Classification
Small molecule
Drug classphosphodiesterase type 9 (PDE9) inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=c1[nH]c(Cc2ccccn2)nc2c1cnn2C1CCOCC1
Identifiers
PDB
CAS-ID1189767-28-9
RxCUI
ChEMBL IDCHEMBL4206492
ChEBI ID
PubChem CID
DrugBank
UNII IDO9OC34WOAY (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
6 adverse events reported
View more details